PURPOSE To detect alterations in DNA damage repair (DDR) genes, measure homologous
recombination deficiency (HRD), and correlate these findings with clinical outcome in …

Leiomyosarcoma (LMS) is a rare, aggressive, mesenchymal tumor. Subsets of LMS have
been identified to harbor genomic alterations associated with homologous recombination …

Background Soft‐tissue sarcomas (STS) describe a heterogeneous group of mesenchymal
tumors with limited treatment options. Targeted therapies exist for BRCA1/2 gene alterations …

Recurrent genomic mutations in uterine and non-uterine leiomyosarcomas have not been
well established. Using a next generation sequencing (NGS) panel of common cancer …

Purpose: Leiomyosarcoma and liposarcoma are common subtypes of soft tissue sarcoma
(STS). Patients with metastatic leiomyosarcoma or dedifferentiated liposarcoma (DDLPS) …

Leiomyosarcoma (LMS) belongs to the class of genetically complex sarcomas and shows
numerous, often non‐recurrent chromosomal imbalances and aberrations. We investigated …

Targeting the DNA damage response (DDR) pathway is an emerging therapeutic approach
for leiomyosarcoma (LMS), and loss of RNase H2, a DDR pathway member, is a potentially …

Purpose: Leiomyosarcoma is a malignant neoplasm with smooth muscle differentiation.
Little is known about its molecular heterogeneity and no targeted therapy currently exists for …

Background: Soft tissue sarcomas are heterogeneous and a major complication in their
management is that the existing classification scheme is not definitive and is still evolving …

Advanced stage leiomyosarcoma (LMS) is incurable with current systemic antitumor
therapies. Therefore, there is clinical interest in exploring novel therapeutic regimens to treat …